Author: Asianet Pakistan

Posted on

AACSB Approves Global Standard-Setting Framework, Paving the Way for the Next Era of Business Education Standards

Transformative Initiative to Shape the Future of Business Education

TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) — AACSB International (AACSB), the world’s leading accrediting body for business schools, has approved the AACSB Global Standard-Setting Framework. This framework formalizes the process for revising business education standards and establishes a structured five-year review cycle. This initiative reaffirms AACSB’s position as the global authority on business education quality and impact.

The AACSB Board of Directors has charged Chief Accreditation Officer Stephanie Bryant with implementing the new framework and initiating a review and revision of the current standards. A global task force comprising key stakeholders from across the business education ecosystem will oversee the revision process to ensure alignment with the evolving needs of business schools, industry, and society.

Anticipated to launch on July 1, 2026, the revised standards will be released as The Global Standards for Business Education™. This initiative reinforces AACSB’s mission to advance the quality and impact of business education, providing more than 17,000 business schools worldwide with a structured framework for continuous improvement and global impact.

“For over a century, AACSB has been the de facto global standard-setting body for business education, guiding institutions toward quality, excellence, and impact,” said Lily Bi, President and CEO of AACSB. “As the business education landscape continues to evolve, AACSB is committed to ensuring that business schools remain agile, innovative, and aligned with industry and societal needs.”

The standards revision process will include an exposure draft and a public comment period, allowing for broad engagement from AACSB’s global community. The final version of The Global Standards for Business Education™ is expected to be voted on at the Annual Business Meeting in April 2026, with official implementation on July 1, 2026.

“The updated standards will provide all business schools with a clear, future-ready framework to drive excellence and innovation,” said Sherif Kamel, Chair of AACSB’s Board of Directors and Dean of Onsi Sawiris School of Business, The American University in Cairo.

About AACSB International

Established in 1916, AACSB International (AACSB) is the world’s largest business education association, representing 1,900 institutional members and 1,000 accredited schools, connecting business schools, businesses, and lifelong learners to create the next generation of great leaders. With members in over 100 countries and territories, AACSB elevates the quality and impact of business schools globally. Learn how AACSB and business schools from around the world are leading boldly in business education at aacsb.edu.

Media Contact:
Andrew Thriffiley
PR Manager, AACSB International
[email protected]
+1 813-769-6500


GlobeNewswire Distribution ID 9351956

Posted on

First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak

The vaccine candidate is being evaluated in a ring vaccination trial as part of a comprehensive public health response

NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / The first participants have been vaccinated with an investigational Ebola Sudan vaccine candidate provided by IAVI, a nonprofit scientific research organization, as part of a World Health Organization (WHO)-led ring vaccination trial taking place at Makerere University Lung Institute in Kampala. WHO prioritized evaluation of IAVI's candidate vaccine, which was already prepositioned in Uganda, as part of a global collaborative effort supporting the country's Ebola outbreak response.

This is Uganda's sixth outbreak of Ebola Sudan, which causes severe hemorrhagic fever disease with a case fatality rate of up to 50%. No licensed vaccines or therapeutics are available for Ebola Sudan, a Category A priority pathogen. Existing Ebola Zaire vaccines are not cross-protective for Ebola Sudan.

Mark Feinberg, M.D., Ph.D., IAVI president and CEO, said: "IAVI is grateful for the efforts that the WHO, the Ugandan government, and our public health partners in Uganda have made in enabling the rapid deployment of our investigational Ebola Sudan vaccine candidate to address the ongoing outbreak of Ebola Sudan in Uganda. We believe this clinical trial represents an important step toward evaluating the potential of IAVI's vaccine to protect exposed individuals from Ebola Sudan infection as well as demonstrating its value as a safe, effective, and accessible new tool to include in comprehensive outbreak responses in the future. Critically, having vaccine doses readily available in country made it possible for us all to mobilize in just days and to be able to incorporate evaluation of a promising Ebola Sudan vaccine clinical trial into the public health response very soon after the first reports of the current outbreak."

Uganda's current Ebola outbreak began on Jan. 30 with a confirmed infection in a health worker who died in Kampala, and since then 45 contacts have been identified. Close contacts are at elevated risk of infection and are prioritized for inclusion in a ring vaccination trial.

A study published recently in the New England Journal of Medicine confirms the high-level effectiveness of ring vaccination in containing Ebola outbreaks in the Democratic Republic of the Congo. The vaccine assessed in that study - ERVEBO®, Merck's single-dose Zaire ebolavirus vaccine - uses the same recombinant vesicular stomatitis virus (rVSV) viral vector platform as IAVI's Ebola Sudan vaccine candidate. ERVEBO® is licensed in more than a dozen countries.

More about IAVI's investigational Ebola Sudan vaccine candidate

In 2023, IAVI initiated a Phase 1 clinical trial of its rVSV-based Ebola Sudan vaccine candidate. The study was designed to evaluate the Ebola Sudan vaccine candidate in healthy U.S. adult volunteers at three dose levels. Initial results from that study indicate that the candidate vaccine was well tolerated across all three groups; immune responses were also detected in all three groups. These data were shared in November 2024 during the annual meeting American Society of Tropical Medicine and Hygiene. As a follow-up to this study, IAVI and our partners are currently planning a Phase 1 study in Africa.

In addition to being the backbone of the Ebola Sudan vaccine candidate, rVSV is the platform technology utilized in IAVI's portfolio of emerging infectious disease (EID) candidates, including a Lassa virus vaccine candidate currently in Phase 2 clinical trials in West Africa, supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European and Developing Countries Clinical Trials Partnership (EDCTP).

Rose Catlos
[email protected]
+12128471049

SOURCE: IAVI



View the original press release on ACCESS Newswire

Posted on

‫منطقة إي إم في بانكوك تعلن عن احتفالاتها المميزة بالعام الصيني الجديد بعرض 3000 باندا احتفاءً بمرور 50 عامًا على الصداقة الدبلوماسية بين تايلاند والصين

بانكوك، تايلاند – Media OutReach Newswire – 29 فبراير 2025 – يسر منطقة إي إم ديستريكت بانكوك أن تعلن عن إقامة احتفال مبهر بالعام الصيني الجديد بمناسبة حلول العام الذهبي للصداقة بين تايلاند والصين. يحتفي هذا الحدث المهم بالذكرى السنوية الخمسين على إقامة العلاقات الدبلوماسية بين البلدين، وستجمع الاحتفالات بين عراقة التراث الثقافي وجاذبية المعالم السياحية المعاصرة. ستقام هذه الاحتفالات المبهجة بحضور معالي السيد هان تشي تشيانج، سفير جمهورية الصين الشعبية لدى مملكة تايلاند، والسيد فومتام ويتشاي تشاي، نائب رئيس الوزراء ووزير الدفاع، والسيد فاراووت سيلبا آرتشا، وزير التنمية الاجتماعية والأمن البشري، والسيدة سوداوان وانجسوفاكيكوسول، وزيرة الثقافة، والسيدة تيرارات سامريجفانيش، نائبة وزير الداخلية، والسيد تشادتشارت سيتيبونت – محافظ بانكوك، والسيدة تاباني كياتفايبول، رئيسة هيئة السياحة في تايلاند، وكبار مديري مجموعة ذا مول بقيادة السيدة سوبالوك أومبوه، رئيسة مجلس إدارة المجموعة، وستُعقد فعاليات الاحتفالات بدايةً من 20 يناير حتى 28 فبراير 2025 في جميع معالم منطقة إي إم الحيوية، بما فيها مراكز إمبوريوم وإم كوارتير وإمسفير التجارية الكبيرة.

خلال الفترة ما بين 22 يناير و23 فبراير، ستضم منطقة إي إم 3000 منحوتة رائعة على شكل دب باندا، وبذلك ستتحول المنطقة إلى معرض ضخم وفريد لدببة الباندا. علاوة على ذلك، ستقدم فرقة باندا فلاش عرضين يوميًا من 27 حتى 29 يناير لنشر مزيد من الإثارة والبهجة بين الأسر والزوار من جميع الأعمار. في 26 و27 يناير، ستتجول شاحنة ثقافة الباندا في جميع أنحاء مدينة بانكوك بدءًا من تقاطع أسوكي حتى القصر الكبير ثم ستتوجه إلى منطقة إي إم لاستعراض سمات النظام البيئي للباندا أمام جميع من في المدينة.

سيستمتع محبو الطعام بمغامرة رائعة في سوق الأطعمة الشعبية الصينية وبيت الشاي بمركز إم كوارتير التجاري. ستضم هذه السوق 30 بائعًا تم اختيارهم بعناية لتقديم مجموعة متنوعة من المأكولات الصينية الأصيلة والشاي التقليدي وأطعمة خفيفة رائعة المذاق وممتعة لجميع الحواس.

سيقام معرض ومقهى باندا في قاعة إي إم ماركت  بمركز إمسفير التجاري، وسيحظى زواره بفرصة لشراء أكثر المنتجات الصينية مبيعًا. سيقام هذا المعرض الفريد في الفترة ما بين 22 يناير و25 فبراير، وسيعرض أفضل المشغولات اليدوية والابتكارات الصينية في بانكوك، مما يتيح لزواره فرصة لاكتشاف معروضاته الحصرية وكنوزه الثقافية.

ستزين زخارف التنين الذهبي الرائعة جميع أنحاء منطقة إي إم احتفالًا بعام التنين الذهبي، كما ستستعرض المراكز التجارية الثلاثة في منطقة إي إم تصميمات مذهلة للتنين الذهبي الذي يرمز إلى الرخاء والقوة والحظ السعيد. تتميز هذه الزخارف بثراء تفاصيلها الأخاذة التي ينجذب إليها الزوار وتنشر الإحساس بالبهجة احتفالًا بالعام الصيني الجديد.

تدعو منطقة إي إم في بانكوك الجميع لحضور هذا الاحتفال التاريخي الذي سيشمل عروض تغيير الوجه الصينية، وحفلات موسيقية، ورقصة مباركة الأسد للاحتفال بمرور خمسة عقود على الصداقة التايلاندية الصينية بإقامة احتفالات مبهجة وفعاليات مميزة وعروض ثقافية جذابة. لا تفوِّت المشاركة في هذا الحدث الذي لا يُنسى والذي يربط عدة ثقافات ومجتمعات في قلب بانكوك.

Posted on

BioAro launches AI-Driven PanOmiQ with Ultrafast Whole Genome Sequencing Analysis Technology

Transforming Genomic Medicine with Unprecedented Speed, Accuracy, and Accessibility – PanOmiQ Sets a New Standard with Analysis Time from VCF Files Under 5 Minutes, and Less Than 2 hrs for FASTQ Files

PanOmiQ

A Revolutionary AI-driven Medical Computing Breakthrough

CALGARY, Alberta, Feb. 03, 2025 (GLOBE NEWSWIRE) — BioAro, a global leader in precision health and genomics, will unveil its groundbreaking AI-powered PanOmiQ platform at the prestigious Precision Medicine World Conference (PMWC) in Silicon Valley. This Whole Genome Sequencing (WGS) solution achieves unparalleled efficiency, reducing analysis time to under two hours and generating Variant Call Format (VCF) files in under five minutes. This historic milestone in medical and computing science redefines the landscape of precision medicine and AI-driven genomic analysis.

BioAro Genomic Lab

State-of-the-art Genomic Analysis Laboratory

This innovation represents a transformative leap in global healthcare, combining speed, accuracy, and affordability to make precision medicine more accessible than ever before. “PanOmiQ isn’t just a technological advancement-it’s a game-changer for global healthcare,” says Dr. Anmol S. Kapoor, Chairman and CEO at BioAro. “By cutting genome analysis time from days to hours, we’re making precision medicine available to everyone, not just the privileged few. This innovation allows clinicians to act on real-time genetic insights, shifting medicine from reactive treatments to proactive, preventative care. This is how we extend human longevity and make personalized health a universal reality.”

PanOmiQ- Real Time Genomics

BioAro’s commitment to innovation is evident in its continuous pursuit of cutting-edge AI-driven solutions that enhance diagnostic accuracy and expand accessibility to genomic medicine. By integrating AI into genomic analysis, PanOmiQ effectively eliminates the bottlenecks of traditional sequencing methods, which have historically been time-consuming and cost prohibitive. This breakthrough enables researchers, healthcare providers, and institutions to expedite precision diagnostics, optimize treatment plans, and significantly reduce the burden on healthcare infrastructure.

Dr. Raja B. Singh, Chief Scientific Officer at BioAro, will showcase PanOmiQ at PMWC, highlighting its ability to democratize precision health through AI-driven genomic technology. By eliminating the high costs and complexity of traditional Whole Genome Sequencing (WGS), PanOmiQ makes advanced genomics accessible to hospitals, researchers, and underserved communities worldwide. This innovation paves the way for new possibilities in cancer research, rare disease diagnostics, and infectious disease monitoring, reinforcing the critical role of AI in shaping the future of healthcare.

One of PanOmiQ’s most remarkable achievements is its proficiency in variant calling. In August 2024, PanOmiQ achieved a 100% match in variant calling during proficiency testing conducted by the College of American Pathologists (CAP), solidifying its position as one of the most accurate genomic platforms available. This level of precision ensures that clinicians and researchers can trust the insights derived from genomic data, leading to better patient care and groundbreaking discoveries.

“We’re not just making genomics faster; we’re making it smarter and more precise,” says Dr. Raja B. Singh. “AI-driven accuracy at this scale ensures that patients receive the most reliable genetic insights, leading to better diagnostics, targeted treatments, and groundbreaking discoveries in fields like cancer research and rare genetic diseases. This is the future of precision medicine.”

The unveiling of PanOmiQ at PMWC Silicon Valley marks a transformative moment in healthcare innovation. By harnessing AI-driven genomic analysis, PanOmiQ enables faster, personalized treatments, reduces healthcare costs, and expands access to precision medicine in underserved regions. From advancing cancer research and rare disease treatments to monitoring infectious diseases in real-time, this groundbreaking platform empowers clinicians and researchers to deliver proactive, preventative care, ultimately improving patient outcomes and extending human longevity.

BioAro Genomic Lab

Healthcare providers worldwide face significant challenges in delivering timely and accurate diagnoses, particularly in regions with limited access to advanced medical technologies. PanOmiQ bridges this gap by providing an efficient, scalable, and cost-effective genomic analysis solution. This advancement is particularly crucial in oncology, where rapid genome sequencing can inform personalized treatment strategies and improve survival rates. Similarly, in the study of rare genetic diseases, PanOmiQ’s capabilities accelerate diagnosis and enable early intervention, transforming patient lives.

PanOmiQ is more than just a Whole Genome Sequencing (WGS) platform-it is the World’s Fastest Multi-Genomic Platform. Its advanced AI-powered analytics extends to Whole Exome Sequencing and microbiome analysis, covering skin, oral, gut, and vaginal microbiomes in real-time. This comprehensive approach to genomics allows researchers and healthcare professionals to gain deeper insights into the interplay between genetics and microbiomes, further advancing the field of precision health.

By integrating microbiome analysis, PanOmiQ enhances the understanding of how microbial ecosystems influence human health. This is particularly relevant in personalized nutrition, immunotherapy, and chronic disease management, where microbiome composition plays a critical role. The ability to conduct real-time microbiome assessments allows clinicians to tailor interventions with unprecedented accuracy, optimizing patient care on an individual level.

“The ability to analyze an entire genome at the population level in under two hours is a historic leap in medical science,” Dr. Kapoor concludes. “We’re not just decoding DNA faster; we’re rewriting the future of healthcare.”

By accelerating genomic analysis and expanding access to precision medicine, PanOmiQ is poised to transform the global healthcare landscape. The implications of this innovation are profound, ranging from improved disease prevention strategies to personalized treatment plans tailored to each patient’s unique genetic profile. As BioAro continues to drive innovation, the company remains steadfast in its mission to make precision health a reality for all.

About BioAro

BioAro is a pioneering precision health and genomics company headquartered in Calgary, Alberta. Specializing in Whole Genome Sequencing, Whole Exome Sequencing, CF-DNA testing, Epigenetics such as Telomere, Methylation, Gene Expression Analysis, Cancer Sequencing, Pharmacogenomics, Microbiome Testing, and AI-Powered Bioinformatics, BioAro is at the forefront of AI-driven healthcare innovation. Through its cutting-edge genomic, longevity, and precision health solutions such as BioELR, Biongevity, The BioSport, and BioGut Clinic, BioAro is transforming patient outcomes, accelerating medical research, and shaping the future of personalized medicine.

Media Contact

Email: [email protected]

Phone: 587-721-2222

Website: www.PanOmiQ.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/0457de01-fb5f-4a9f-a6af-64296a22e37d
https://www.globenewswire.com/NewsRoom/AttachmentNg/43077e77-e7dd-4b1c-b7af-821d04b92355

GlobeNewswire Distribution ID 9351417

Posted on

‫أسترازينيكا تحتل أعلى المراكز بين أفضل أماكن العمل بشمال أفريقيا والشام في عام 2024

دبي، الإمارات العربية المتحدة – Media OutReach Newswire – 3 فبراير 2025 – أسترازينيكا، الشركة الرائدة متعددة الجنسيات المتخصصة في مجال الأدوية والتكنولوجيا الحيوية، حصلت على لقب ثاني أفضل مكان عمل في منطقة الشرق الأوسط لعام 2024 وفقًا لتصنيف “أفضل أماكن العمل” السنوي المرموق.

حصلت الشركة على مركزًا مميزًا على المستوى القُطري المخصص في تصنيفات أفضل أماكن العمل، كما أنها حصلت على لقب أفضل مكان عمل للنساء وأفضل مكان عمل لأبناء جيل الألفية في أسواق راقية.

شغلت أسترازينيكا المركز الأول في العراق والجزائر ولبنان، بينما حصلت على المركز الثاني في المغرب وتونس، وحصلت على المركز الثالث في الأردن. في العام الماضي، شغلت أسترازينيكا المرتبة الثانية في منطقة الشرق الأوسط، وهذا يدل على استمرار تقدير ثقافة مكان العمل لديها ويعزز مكانتها بصفتها مكان عمل مفضل في المنطقة.

رامي اسكندر، رئيس الأعمال في منطقة الشرق الأدنى ودول المغرب، قال في تصريح له: “إنه لأمر يدعوني إلى الفخر والامتنان أن أشهد الإنجازات الرائعة التي تحققها أسترازينيكا في منطقة الشرق الأدنى ودول المغرب باستمرار. بعدما أُعلن مؤخرًا عن تصنيفنا ضمن أفضل أماكن العمل، يسرني أن أعلن حصولنا على المركزين الأول والثاني في الشرق الأوسط. يشهد هذا الإنجاز المتميز حقًا على عملكم الجاد وتفانيكم والتزامكم بالتميز.”

علقت هبة الشبراوي، مديرة الموارد البشرية في شركة أسترازينيكا الشرق الأدنى والمغرب، على هذا الإنجاز قائلةً: “رغم التحديات العديدة التي تواجهها شركة أسترازينيكا الشرق الأدنى ودول المغرب باستمرار، ما زلنا مبهورين بالمواهب الفذة والالتزام والشغف الذي أظهره أعضاء فريقنا. يُعد تحقيق المركزين الأول والثاني في جميع أسواقنا المشاركة شاهدًا حقيقيًا على الخطوات الرائعة التي اتخذناها على مدار العام الماضي. أود أن أغتنم هذه الفرصة للتعبير عن امتناني لعملكم الجاد ومثابرتكم”.

أظهرت شركة أسترازينيكا الشرق الأدنى والمغرب باستمرار التزامها بتعزيز ثقافة مكان العمل الإيجابية والشاملة، ولذلك استحقت الحصول على شهادة أفضل مكان عمل المرموقة لعدة سنوات متتالية. يدل هذا الإنجاز على تفاني الشركة في تهيئة بيئة عمل يشعر فيها الموظفون بالتقدير والتمكين والتحفيز للتفوق. تتميز شركة أسترازينيكا الشرق الأدنى والمغرب بإعطاء الأولوية للرعاية والنمو والتنوع.

لمعرفة مزيد من المعلومات عن أسترازينيكا، يرجى زيارة www.astrazeneca.com .

لمعرفة مزيد من المعلومات عن برنامج إصدار شهادات أفضل أماكن العمل، يرجى زيارة www.bestplacestowork.com

 

Posted on

Relo Metrics, Meltwater Team Up to Redefine Sponsorship Measurement in Sports and Entertainment

SANTA MONICA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) — Relo Metrics, the leading sports measurement platform, and Meltwater, a leading global provider of media, social, and consumer intelligence, today announced a new partnership that will transform how sports and entertainment customers measure and maximize sponsorship performance in the digital landscape. This collaboration will enable customers to unlock unparalleled insights with Relo’s AI-powered sponsorship analytics platform alongside Meltwater’s media intelligence solutions.

2024 has been the year of sports, and the overall live entertainment industry continues to have a renaissance worldwide. The need for all parties to ensure that their messages are breaking through, and that all the value is being properly measured has risen in strategic importance.

The vast digital media landscape, the thousands of websites that cover sports, entertainment, and news are the source of trillions of impressions worldwide. Previously all of that engagement and brand exposure in stories, photos, and videos was not being measured and valued in relation to a brand and a sports team, or a brand and an entertainment event. With this partnership, customers will now gain access to even more actionable insights on sponsorship performance including media values and impressions, alongside all the other channels of measurement in the Relo and Meltwater platforms.

The primary customer profiles benefiting from this partnership include:

  • Rights Holders (Sports Properties, Teams, and Leagues): Closing the gap between marketing, social, PR/comms and partnership sales teams with insights that measure partner performance across the season, assisting with renewing partnerships and growing revenue potential.
  • Brands: Within marketing there are planning and execution teams that cut across all marketing and communication channels uniting it with media strategy and experiential marketing.
  • Agencies: This partnership will enable various agencies within PR, Media, and Sports to collaborate on data strategy and measurement.

“This partnership with Meltwater is a game-changer for the sports and entertainment industry. By providing even more insights into media and sponsorship measurement we are unlocking a massive, previously untapped source of brand value,” said Jay Prasad, CEO of Relo Metrics. “By adding additional media insights alongside broadcast and social exposure, we’re empowering rights holders, brands, and agencies to see the full picture of their sponsorship performance, and ultimately drive more strategic and data-backed decisions. This is a huge leap forward in delivering actionable insights that transform how sponsorships are valued.”

Meltwater’s suite of solutions unlocks the power of media, social, and consumer data, transforming them into actionable insights to give customers a competitive edge. With the most comprehensive dataset in the industry and more than 1 billion pieces of media and social content analyzed each day, Meltwater empowers companies with easy-to-action insights that drive data-backed decision-making. Its suite of solutions spans media intelligence, media relations, social listening, social media management, influencer marketing, consumer intelligence, and more.

For brands, agencies, rights holders, and media companies who seek to maximize the impact and ROI of their sports sponsorship investments, Relo Metrics provides unparalleled performance analytics that delivers granular insights and full-funnel measurement. Relo differentiates itself by offering deterministic conversion and attribution metrics, empowering stakeholders to understand the true value and outcomes of their sponsorships.

A key part of this strategy is Relo Metrics’ partner ecosystem by which is enabling Relo to go beyond valuation, named strategic partnerships with complementary technologies in the sports marketing space, giving clients a complete picture of their sponsorship performance.

“In today’s rapidly-evolving media landscape, it’s critical that brands have a comprehensive view of their performance and brand value across all channels. Meltwater is excited to partner with Relo Metrics to enable brands, agencies, rights holders, and media companies to gain a more holistic view of the impact of their sponsorships and optimize their strategies to reach even greater heights,” said Doug Balut, SVP of Global Alliances and Partnerships at Meltwater.

Relo Metrics
Relo Metrics is an AI-powered sponsorship analytics platform that enables brands to track and optimize their sponsorship investments and powers teams and leagues with the insights they need to retain and grow revenue. The company tracks sponsor exposure across live broadcasts, social media, and streaming platforms and delivers actionable insights via a fast, single-solution platform. For more information, visit www.relometrics.com

Meltwater
Meltwater empowers companies with a suite of solutions that spans media, social, consumer and sales intelligence. By analyzing ~1 billion pieces of content each day and transforming them into vital insights, Meltwater unlocks the competitive edge to drive results. With 27,000 global customers, 50 offices across six continents and 2,300 employees, Meltwater is the industry partner of choice for global brands making an impact. Learn more at meltwater.com.

Contacts:
Hannah Shain, VP Marketing, Relo Metrics, [email protected]
Jonalyn Morris (US) / Shawn Belluigi (EMEA), Bubble Agency, [email protected]

GlobeNewswire Distribution ID 9351610